Literature DB >> 23776932

Identifying Marine-Lenhart syndrome on a (99m)Tc-pertechnetate thyroid scan.

Nishikant A Damle1, Rohini Mishra.   

Abstract

Entities:  

Year:  2013        PMID: 23776932      PMCID: PMC3683234          DOI: 10.4103/2230-8210.109698

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, Graves disease coexistent with a nodular goiter is referred to as Marine-Lenhart syndrome. It is also called nodular Graves disease.[1] We present here the technetium pertechnetate thyroid scan image with an emphasis for endocrinologists and nuclear medicine physicians to identify this variant, as it is more resistant to radioiodine than the classical diffuse toxic goiter of Graves disease. A 38-year-old male presented to our institution with complaints of weight loss and tremors since 2 months. His thyroid profile was suggestive of thyrotoxicosis. A thyroid scan done 20 minutes after intravenous administration of 5 mCi 99mTc-Pertechnetate showed an enlarged thyroid with intense uptake in both lobes as well as a left thyroid nodule with intense uptake [Figure 1]. Background tracer activity was suppressed. His Radioactive Iodine Uptake (RAIU) was 31.8% at 2 h (laboratory normal (5-15%)) and 83.6% at 24 h (laboratory normal (15-35%)).
Figure 1

99mTc-pertechnetate thyroid scan showing an enlarged thyroid with intense uptake in both lobes as well as a left thyroid nodule (arrow) with intense uptake [Figure 1]. Background tracer activity appears suppressed

99mTc-pertechnetate thyroid scan showing an enlarged thyroid with intense uptake in both lobes as well as a left thyroid nodule (arrow) with intense uptake [Figure 1]. Background tracer activity appears suppressed The association of thyroid nodules with Graves disease is found in 25-30%[23] of patients affected by Graves disease. More than 95% of these nodules are hypoactive and a small percentage is hyperactive. Therefore, patients with Marine–Lenhart syndrome can have thyrotoxicosis due to the Graves disease as well as the nodule, which may be hyperfunctioning at the outset or may develop autonomicity after a variable period of time.[456] Genetic alterations of the thyroid stimulating hormone TSH receptors are suspected in the development of the Marine–Lenhart syndrome in patients affected by the Graves disease. The amount of radioiodine required to relieve the hyperthyroidism in these patients is greater than the corresponding mean, median, or mode dose required for patients with diffuse toxic goiter. This is said to be the result of the large size of these goiters as well as the relative radio-resistance of some of them.[1] This variant of Graves disease should therefore be kept in mind.
  6 in total

1.  Diagnosis of Marine-Lenhart syndrome.

Authors:  Mehtap Cakir
Journal:  Thyroid       Date:  2004-07       Impact factor: 6.568

2.  Marine-Lenhart syndrome.

Authors:  Milena Braga-Basaria; Shehzad Basaria
Journal:  Thyroid       Date:  2004-12       Impact factor: 6.568

3.  Marine-Lenhart syndrome.

Authors:  Mehtap Cakir
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

4.  Graves' disease with functioning nodules (Marine-Lenhart syndrome).

Authors:  N D Charkes
Journal:  J Nucl Med       Date:  1972-12       Impact factor: 10.057

5.  Thyroid nodules in Graves' disease: implications in an endemically iodine deficient area.

Authors:  A Mishra; S K Mishra
Journal:  J Postgrad Med       Date:  2001 Oct-Dec       Impact factor: 1.476

6.  Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease.

Authors:  Won Bae Kim; Seong-Min Han; Tae Yong Kim; Il Seong Nam-Goong; Gyungyub Gong; Ho Kyu Lee; Suck Joon Hong; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

  6 in total
  2 in total

1.  Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan.

Authors:  Hirosuke Danno; Eijun Nishihara; Kazuyoshi Kousaka; Tomohiko Nakamura; Toshihiko Kasahara; Takumi Kudo; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Akira Miyauchi
Journal:  Eur Thyroid J       Date:  2020-09-30

2.  Marine-Lenhart Syndrome: Case Report, Diagnosis, and Management.

Authors:  Danielle Neuman; Russ Kuker; Francesco Vendrame
Journal:  Case Rep Endocrinol       Date:  2018-10-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.